Targeted biocides
CA 2525961 C · Owner: Iogenetics, Llc · Inventors: Homan, Jane; Bremel, Robert D.; Imboden, Michael
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention relates to retroviral constructs that encode novel monoclonal antibodies, novel fusion proteins and chimeric monoclonal , antibodies and to methods of using and producing the same. In particular the , present invention relates to methods of producing a fusion protein comprising a microorganism targeting molecule (e.g. immunoglobulin. or innate immune system receptor molecule) and a biocide (e.g. bactericidal enzymes) in transgenic animals (e.g. bovines) and in cell cultures. The present invention also relates to therapeutic and prophylactic methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in health care (e.g. human …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed May 14, 2004 and granted August 7, 2012. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended May 14, 2024.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by May 14, 2026.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.